索拉非尼联合肝动脉化疗栓塞术治疗中晚期肝癌的有效性和安全性分析  

Analysis of efficacy and safety of sorafenib combined with transcatheter arterial chemoembolization in treatment of advanced hepatocellular carcinoma

作　　者：王冰[1,2] 贾佳[2] 孙百军[1] 

机构地区：[1]中国人民解放军第302医院肝胆外科,北京市100039 [2]河北北方学院研究生部,河北省张家口市075000

出　　处：《临床合理用药杂志》2015年第25期25-26,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的评价索拉非尼联合肝动脉化疗栓塞术(TACE)治疗中晚期肝癌的有效性和安全性。方法选取中国人民解放军第302医院2012年2月-2013年8月收治的中晚期肝癌患者50例。其中单纯TACE治疗患者28例(单纯组),索拉非尼联合TACE治疗患者22例(联合组)。比较2组的总有效率、中位无进展生存期(PFS)及不良反应发生情况。结果联合组的总有效率为63.6%高于单纯组的17.9%,联合组的PFS为(9.41±1.79)个月长于单纯组约(4.50±1.23)个月,差异均有统计学意义(P<0.01)。2组均未出现严重不良反应。结论索拉非尼联合TACE治疗中晚期肝癌是安全、有效的,值得临床推广。Objective To evaluate the efficacy and safety of sorafenib combined with transcatheter arterial chemoembolization（ TACE） in the treatment of advanced hepatocellular carcinoma. Methods Selected 50 patients with advanced hepatocellular carcinoma from February 2012 to August 2013 in No. 302 Military Hospital of PLA. 28 patients treated with TACE alone（ simple group）,22 patients treated with TACE combined with sorafenib（ combination group）. Compared the total efficiency,progression-free survival（ PFS） and dverse events of two groups. Results The total effective rate of combination group was63. 6% higher than 17. 9% of simple group; The PFS of combination group were（ 9. 41 ± 1. 79） months shorter than（ 4. 50 ±1. 23） months of simple group,the difference was statistically significant（ P 0. 01）. No serious adverse reactions occurred of two group. Conclusion Sorafenib combined with TACE in the treatment of advanced liver cancer is safe and effective,worthy of clinical promotion.

关 键 词：中晚期肝癌 索拉非尼 肝动脉化疗栓塞术 安全性 

分 类 号：R735.7[医药卫生—肿瘤]